CAJ | 학술논문

目的：评价妈咪爱对新生儿高胆红素血症(NHBE)的佐治作用,为进一步临床实践提供证据.方法：检索 Cochrane Li-brary(2012年第6期)、PubMed、Medline、Embase、中国学术期刊网络出版总库、万方数据库、维普数据库等,收集有关妈咪爱佐治NHBE的 RCT文献,检索文献起止时间均为建库至2012年10月.由2名作者进行资料提取和文献质量评价.应用 RevMan5．2软件进行Meta分析,根据异质性结果选择相应的效应模型分析；无法进行 Meta 分析时采用描述性分析.结果：13个 RCT 进入 Meta分析,全部文献均描述了具体随机化方法,但没有采用充分的分配隐藏和盲法；13篇均为中度偏倚风险.Meta 分析结果显示,诊断NHBE共计2061例,妈咪爱佐治组为53．13％,对照组为46．87％,日均胆红素下降值比较MD＝15．52,95％CI(11．99,19．05),P＜0．00001,差异有统计学意义；胆红素下降至正常值需要的治疗时间比较 MD＝-1．83,95％CI(-2．10,-1．55),P＜0．00001,差异有统计学意义.结论：Meta分析结果支持妈咪爱佐治 NHBE,建议开展设计更加科学,执行更加严谨的多中心大样本临床试验.
목적：평개마미애대신생인고담홍소혈증(NHBE)적좌치작용,위진일보림상실천제공증거.방법：검색 Cochrane Li-brary(2012년제6기)、PubMed、Medline、Embase、중국학술기간망락출판총고、만방수거고、유보수거고등,수집유관마미애좌치NHBE적 RCT문헌,검색문헌기지시간균위건고지2012년10월.유2명작자진행자료제취화문헌질량평개.응용 RevMan5．2연건진행Meta분석,근거이질성결과선택상응적효응모형분석；무법진행 Meta 분석시채용묘술성분석.결과：13개 RCT 진입 Meta분석,전부문헌균묘술료구체수궤화방법,단몰유채용충분적분배은장화맹법；13편균위중도편의풍험.Meta 분석결과현시,진단NHBE공계2061례,마미애좌치조위53．13％,대조조위46．87％,일균담홍소하강치비교MD＝15．52,95％CI(11．99,19．05),P＜0．00001,차이유통계학의의；담홍소하강지정상치수요적치료시간비교 MD＝-1．83,95％CI(-2．10,-1．55),P＜0．00001,차이유통계학의의.결론：Meta분석결과지지마미애좌치 NHBE,건의개전설계경가과학,집행경가엄근적다중심대양본림상시험.
Objective:To evaluate adjunctive ly therapeutic effect of Medilac-Vita for Neonatal Hyperbil-irubinemia (NHBE,and to provide some clinically practical evidence.Methods:Cochrane Library(issue 6, 2012),PubMed,Medline,Embase,China academic journal network publishing data library,Wangfang data library,and Weipu data library were searched,and Randomized Controlled Trials(RTC)of Medilac-Vita’ adjunctively therapeutic effect for Neonatal Hyperbilirubinemia were involved.The time of bibliographic re-trieval was from when the databases existed to October 2012.2 authors collected the data and evaluated qual-ity of data.Software of RevMan5 .2 was applied.Different Effect model analysis was chosen according to het-erogeneity results,while descriptive analysis failed to be done by meta analysis was adopted.Results:1 3 RCT were invlved,all of which descriped detailed randomization method,but there were no adopted sufficient allo-cation concealment and blinding,and showed medium risk of bias.It showed that 2061 patients were diag-nosed as NHBE,with 53.13% treated by Medilac-Vita,and 46.87% as control group.Comparison MD of av-erage daily bilirubin decreased value was 15.52,with 95%CI(11.99,19.05)and statistically significant differ-ence (P<0.00001).Comparison MD of therapeutic time how long bilirubin drops to normal was1.83,with 95%CI (-2.10,-1.55),and statistically significant difference (P<0.00001).Conclusion:Our results sup-port Medilac-Vita’adjunctively therapeutic effect for Neonatal Hyperbilirubinemia.To further confirm, more scientific designs and rigorous multicenter,large sample clinical trials should be carried out.